Physician profile
William Durrett
NPI 1215946538
$8,278.46
in general payments reported to CMS, 2019-2025
39 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $1,519 · 2021: $1,326 · 2022: $1,441 · 2023: $725 · 2024: $760 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,451.05 | 2019-2025 | Eterna, Octrode, Ionicrf |
| Forte Bio-Pharma LLC | $903.20 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Flowonix Medical Incorporated | $725.95 | 2019-2020 | |
| Nevro Corp. | $517.78 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $517.44 | 2019-2022 | |
| Abbvie INC. | $338.72 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $334.63 | 2019-2025 | |
| Azurity Pharmaceuticals, INC. | $332.30 | 2023-2025 | Horizant, Horizant |
| Ibsa Pharma INC. | $268.86 | 2021-2024 | Tirosint, Licart, Licart |
| Scilex Pharmaceuticals INC. | $260.11 | 2019-2023 | Ztlido |
| Acelrx Pharmaceuticals, INC. | $163.14 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $140.75 | 2019-2022 | |
| Allergan, INC. | $129.32 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.11 | 2019-2022 | |
| Assertio Therapeutics, INC. | $112.55 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $112.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $79.30 | 2020-2021 | |
| Virtus Pharmaceuticals LLC | $78.62 | 2020-2021 | |
| Amgen INC. | $77.02 | 2021 | |
| Zyla Life Sciences, INC. | $66.91 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $58.60 | 2020-2022 | |
| Vertos Medical, INC. | $56.06 | 2019 | |
| Lundbeck LLC | $55.43 | 2022-2023 | Vyepti |
| Hikma Pharmaceuticals USA | $53.75 | 2022 | |
| Boston Scientific Corporation | $45.63 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $39.73 | 2019-2021 | |
| Lilly USA, LLC | $33.13 | 2020-2024 | Emgality |
| Convatec INC. | $30.32 | 2025 | |
| Kaleo, INC. | $24.68 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.11 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.07 | 2022 | |
| Redhill Biopharma INC. | $16.85 | 2020 | |
| Medtronic, INC. | $16.35 | 2022 | |
| Almatica Pharma LLC | $15.49 | 2021 | |
| Averitas Pharma INC. | $15.25 | 2023 | Qutenza |
| Si-Bone, INC. | $15.15 | 2019 | |
| Protega Pharmaceutials INC | $15.11 | 2023 | Roxybond |
| Nalu Medical, INC. | $13.90 | 2021 | |
| Spinal Simplicity, LLC | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Durrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.